Mitoxantrone Baxter (Mitoxantrone Hydrochloride)

Mitoxantrone Hydrochloride intercalates into DNA and blocks topoisomerase II activity, which prevents the re‑ligation of DNA strands during replication. This leads to accumulation of DNA breaks, triggering apoptosis of rapidly dividing cells such as cancer cells and immune cells involved in multiple sclerosis.

The dosage of Mitoxantrone Baxter is determined by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and prior treatment history. Only a qualified healthcare professional should calculate and administer the appropriate dose.

The safety of Mitoxantrone during pregnancy or lactation has not been established. It is classified as having an unknown pregnancy category, and the drug may cause fetal harm. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a specialist.

To order Mitoxantrone Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mitoxantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin by having a distinct DNA intercalation profile and a lower incidence of certain cardiotoxic effects at comparable doses. However, it still carries a risk of cardiac toxicity and secondary leukemia, so clinicians weigh these factors when selecting therapy.

Mitoxantrone Baxter should be stored at 2‑8 °C in a refrigerator. The vials must be kept in their original packaging, protected from light, and should never be frozen or shaken. Follow the manufacturer’s instructions to maintain product stability.

Mitoxantrone Baxter is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of several minutes to an hour, depending on the prescribed protocol and patient tolerance.

The most serious risks include cardiotoxicity leading to heart failure, the development of secondary acute leukemia, severe infections due to bone‑marrow suppression, and hepatic or pulmonary toxicity. Patients should be monitored closely for cardiac function, blood counts, liver enzymes, and respiratory symptoms throughout treatment.

Mitoxantrone Baxter should be avoided in patients with known hypersensitivity to the drug, uncontrolled cardiac disease, recent exposure to high cumulative doses of anthracyclines, active severe infections, or in those who are pregnant or breastfeeding unless absolutely necessary.